Ethical issues in establishing the efficacy and safety of long-acting injectable pre-exposure prophylaxis for HIV prevention: the HPTN 083 trial

被引：3
|
作者：
Sugarman, Jeremy [1 ,2 ]
Donnell, Deborah J. [3 ]
Hanscom, Brett [3 ]
McCauley, Marybeth [4 ]
Grinsztejn, Beatriz [5 ]
Landovitz, Raphael J. [6 ]
机构：
[1] Johns Hopkins Univ, Berman Inst Bioeth, Baltimore, MD 21205 USA
[2] Johns Hopkins Univ, Dept Med, Baltimore, MD USA
[3] Fred Hutchison Canc Res Ctr, Vaccine & Infect Dis Div, Seattle, WA USA
[4] HIV Prevent Trials Network Leadership & Operat Ct, Washington, DC USA
[5] Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, Brazil
[6] UCLA, Ctr Clin AIDS Res & Educ, Los Angeles, CA USA
来源：
LANCET HIV | 2021年 / 8卷 / 11期
基金：
美国国家卫生研究院;
关键词：
PROTECTS MACAQUES; CABOTEGRAVIR;
D O I：
10.1016/S2352-3018(21)00153-3
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Two multinational clinical trials have shown safety and efficacy of long-acting injectable cabotegravir for HIV preexposure prophylaxis (PrEP). These results will alter the landscape of HIV prevention and related research. Nevertheless, designing and conducting this research involved several ethical issues. This Viewpoint describes how we managed ethical issues over the duration of one of these trials (HPTN 083). Specifically, we discuss the rationale for pursuing a long-acting injectable agent in the presence of effective oral PrEP, trial design choices, site selection and local standards of prevention, data monitoring and early stopping, effects of the COVID-19 pandemic, post-trial access, and assessment of long-term safety.
引用
收藏
页码：E723 / E728
页数：6
相关论文
共 50 条
  • [31] Pre-exposure prophylaxis of non-HIV viral infections and the role of long-acting antivirals
    Soriano, Vicente
    Moreno-Torres, Victor
    de Mendoza, Carmen
    Fernandez-Montero, Jose V.
    Trevino, Ana
    Corral, Octavio
    de Jesus, Fernando
    Barreiro, Pablo
    AIDS REVIEWS, 2023, 25 (04) : 162 - 172
  • [32] Improving preparedness for introducing and scaling up long-acting HIV pre-exposure prophylaxis in Asia
    Bavinton, Benjamin R.
    Schmidt, Heather-Marie A.
    Mills, Stephen
    Phanuphak, Nittaya
    SEXUAL HEALTH, 2024, 21 (04)
  • [33] Epidemiological impact and cost-effectiveness of providing long-acting pre-exposure prophylaxis to injectable contraceptive users for HIV prevention in South Africa: a modelling study
    van Vliet, Marjolein M.
    Hendrickson, Cheryl
    Nichols, Brooke E.
    Boucher, Charles A. B.
    Peters, Remco P. H.
    van de Vijver, David A. M. C.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2019, 22 (12)
  • [34] Barriers and Facilitators to Long-Acting Injectable HIV Pre-Exposure Prophylaxis Implementation in Primary Care Since Its Approval in the United States
    Keddem, Shimrit
    Thatipelli, Sneha
    Caceres, Omaris
    Roder, Navid
    Momplaisir, Florence
    Cronholm, Peter
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2024, 95 (04) : 370 - 376
  • [35] Familiarity with and Preferences for Oral and Long-Acting Injectable HIV Pre-exposure Prophylaxis (PrEP) in a National Sample of Gay and Bisexual Men in the US
    Parsons, Jeffrey T.
    Rendina, H. Jonathon
    Whitfield, Thomas H. F.
    Grov, Christian
    AIDS AND BEHAVIOR, 2016, 20 (07) : 1390 - 1399
  • [36] Long acting systemic HIV pre-exposure prophylaxis: an examination of the field
    William R. Lykins
    Ellen Luecke
    Daniel Johengen
    Ariane van der Straten
    Tejal A. Desai
    Drug Delivery and Translational Research, 2017, 7 : 805 - 816
  • [37] Long acting systemic HIV pre-exposure prophylaxis: an examination of the field
    Lykins, William R.
    Luecke, Ellen
    Johengen, Daniel
    van der Straten, Ariane
    Desai, Tejal A.
    DRUG DELIVERY AND TRANSLATIONAL RESEARCH, 2017, 7 (06) : 805 - 816
  • [38] Multitasking Pharmacophores Support Cabotegravir-Based Long-Acting HIV Pre-Exposure Prophylaxis (PrEP)
    Wan, Zheng
    Shi, Man
    Gong, Yanqing
    Lucci, Massimo
    Li, Jinjin
    Zhou, Jiahai
    Yang, Xiao-Liang
    Lelli, Moreno
    He, Xiao
    Mao, Jiafei
    MOLECULES, 2024, 29 (02):
  • [39] A Compartmental Pharmacokinetic Evaluation of Long-Acting Rilpivirine in HIV-Negative Volunteers for Pre-Exposure Prophylaxis
    Jackson, A. G. A.
    Else, L. J.
    Mesquita, P. M. M.
    Egan, D.
    Back, D. J.
    Karolia, Z.
    Ringner-Nackter, L.
    Higgs, C. J.
    Herold, B. C.
    Gazzard, B. G.
    Boffito, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 96 (03) : 314 - 323
  • [40] Safety and Pharmacokinetic Profiles of Long-Acting Injectable Antiretroviral Drugs for HIV-1 Pre-Exposure Prophylaxis: A Systematic Review and Meta-analysis of Randomized Trials
    Lazarus, Gilbert
    Wangsaputra, Vincent Kharisma
    Christianto
    Louisa, Melva
    Soetikno, Vivian
    Hamers, Raph L.
    FRONTIERS IN PHARMACOLOGY, 2021, 12
12345